{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:27:13Z","timestamp":1790011633400,"version":"4.0.1"},"reference-count":184,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NCI","award":["R01CA237401-01A1"],"award-info":[{"award-number":["R01CA237401-01A1"]}]},{"name":"NIH\/NCI","award":["DBG-23-1152703-01-TBE"],"award-info":[{"award-number":["DBG-23-1152703-01-TBE"]}]},{"name":"NIH\/NCI","award":["#857709"],"award-info":[{"award-number":["#857709"]}]},{"name":"NIH\/NCI","award":["#T32 CA009120"],"award-info":[{"award-number":["#T32 CA009120"]}]},{"name":"American Cancer Society Discovery Boost","award":["R01CA237401-01A1"],"award-info":[{"award-number":["R01CA237401-01A1"]}]},{"name":"American Cancer Society Discovery Boost","award":["DBG-23-1152703-01-TBE"],"award-info":[{"award-number":["DBG-23-1152703-01-TBE"]}]},{"name":"American Cancer Society Discovery Boost","award":["#857709"],"award-info":[{"award-number":["#857709"]}]},{"name":"American Cancer Society Discovery Boost","award":["#T32 CA009120"],"award-info":[{"award-number":["#T32 CA009120"]}]},{"name":"LUNGevity Foundation Lung Cancer Early Detection","award":["R01CA237401-01A1"],"award-info":[{"award-number":["R01CA237401-01A1"]}]},{"name":"LUNGevity Foundation Lung Cancer Early Detection","award":["DBG-23-1152703-01-TBE"],"award-info":[{"award-number":["DBG-23-1152703-01-TBE"]}]},{"name":"LUNGevity Foundation Lung Cancer Early Detection","award":["#857709"],"award-info":[{"award-number":["#857709"]}]},{"name":"LUNGevity Foundation Lung Cancer Early Detection","award":["#T32 CA009120"],"award-info":[{"award-number":["#T32 CA009120"]}]},{"name":"UCLA Tumor Immunology Training","award":["R01CA237401-01A1"],"award-info":[{"award-number":["R01CA237401-01A1"]}]},{"name":"UCLA Tumor Immunology Training","award":["DBG-23-1152703-01-TBE"],"award-info":[{"award-number":["DBG-23-1152703-01-TBE"]}]},{"name":"UCLA Tumor Immunology Training","award":["#857709"],"award-info":[{"award-number":["#857709"]}]},{"name":"UCLA Tumor Immunology Training","award":["#T32 CA009120"],"award-info":[{"award-number":["#T32 CA009120"]}]},{"name":"Bill and Melinda Gates Foundation","award":["R01CA237401-01A1"],"award-info":[{"award-number":["R01CA237401-01A1"]}]},{"name":"Bill and Melinda Gates Foundation","award":["DBG-23-1152703-01-TBE"],"award-info":[{"award-number":["DBG-23-1152703-01-TBE"]}]},{"name":"Bill and Melinda Gates Foundation","award":["#857709"],"award-info":[{"award-number":["#857709"]}]},{"name":"Bill and Melinda Gates Foundation","award":["#T32 CA009120"],"award-info":[{"award-number":["#T32 CA009120"]}]},{"name":"Eugene V. Cota-Robles Fellowship at UCLA","award":["R01CA237401-01A1"],"award-info":[{"award-number":["R01CA237401-01A1"]}]},{"name":"Eugene V. Cota-Robles Fellowship at UCLA","award":["DBG-23-1152703-01-TBE"],"award-info":[{"award-number":["DBG-23-1152703-01-TBE"]}]},{"name":"Eugene V. Cota-Robles Fellowship at UCLA","award":["#857709"],"award-info":[{"award-number":["#857709"]}]},{"name":"Eugene V. Cota-Robles Fellowship at UCLA","award":["#T32 CA009120"],"award-info":[{"award-number":["#T32 CA009120"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer cells utilize larger amounts of glucose than their normal counterparts, and the expression of GLUT transporters is a known diagnostic target and a prognostic factor for many cancers. Recent evidence has shown that sodium-glucose transporters are also expressed in different types of cancer, and SGLT2 has raised particular interest because of the current availability of anti-diabetic drugs that block SGLT2 in the kidney, which could be readily re-purposed for the treatment of cancer. The aim of this article is to perform a narrative review of the existing literature and a critical appraisal of the evidence for a role of SGLT2 inhibitors for the treatment and prevention of cancer. SGLT2 inhibitors block Na-dependent glucose uptake in the proximal kidney tubules, leading to glycosuria and the improvement of blood glucose levels and insulin sensitivity in diabetic patients. They also have a series of systemic effects, including reduced blood pressure, weight loss, and reduced inflammation, which also make them effective for heart failure and kidney disease. Epidemiological evidence in diabetic patients suggests that individuals treated with SGLT2 inhibitors may have a lower incidence and better outcomes of cancer. These studies are confirmed by pre-clinical evidence of an effect of SGLT2 inhibitors against cancer in xenograft and genetically engineered models, as well as by in vitro mechanistic studies. The action of SGLT2 inhibitors in cancer can be mediated by the direct inhibition of glucose uptake in cancer cells, as well as by systemic effects. In conclusion, there is evidence suggesting a potential role of SGLT2 inhibitors against different types of cancer. The most convincing evidence exists for lung and breast adenocarcinomas, hepatocellular carcinoma, and pancreatic cancer. Several ongoing clinical trials will provide more information on the efficacy of SGLT2 inhibitors against cancer.<\/jats:p>","DOI":"10.3390\/cancers17030466","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:40:46Z","timestamp":1738215646000},"page":"466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities"],"prefix":"10.3390","volume":"17","author":[{"given":"Aparamita","family":"Pandey","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Drive, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8750-752X","authenticated-orcid":false,"suffix":"Jr.","given":"Mart\u00edn","family":"Alcaraz","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Drive, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Saggese","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnologies Charles Darwin, University of Rome \u201cSapienza\u201d, Piazzale Aldo Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Soto","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Drive, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefany","family":"Gomez","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Drive, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Jaldu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Drive, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Drive, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Scafoglio","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Drive, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Martinez, C.A., and Scafoglio, C. (2020). Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules, 10.","DOI":"10.3390\/biom10060868"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2008.09.005","article-title":"Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond","volume":"121","author":"Ganapathy","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/iub.315","article-title":"The protein family of glucose transport facilitators: It\u2019s not only about glucose after all","volume":"62","author":"Augustin","year":"2010","journal-title":"IUBMB Life"},{"key":"ref_5","first-page":"285","article-title":"Facilitative glucose transporter expression in human cancer tissue","volume":"56","author":"Smith","year":"1999","journal-title":"Br. J. Biomed. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2014","journal-title":"Pflugers Arch."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2001.tb01175.x","article-title":"SGLT gene expression in primary lung cancers and their metastatic lesions","volume":"92","author":"Ishikawa","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"ref_10","first-page":"199","article-title":"MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer","volume":"54","author":"Zhang","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2018.06.004","article-title":"Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the 18F-FDG PET\/CT mediastinal nodal staging of non-small cell lung cancer","volume":"123","author":"Taira","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"C1277","DOI":"10.1152\/ajpcell.00296.2010","article-title":"Functional expression of SGLTs in rat brain","volume":"299","author":"Yu","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","article-title":"SGLT2 and cancer","volume":"472","author":"Wright","year":"2020","journal-title":"Pflugers Arch."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"eaat5933","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41419-022-04980-w","article-title":"SGLT2 inhibitor activates the STING\/IRF3\/IFN-beta pathway and induces immune infiltration in osteosarcoma","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.celrep.2019.07.027","article-title":"p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas","volume":"28","author":"Hsieh","year":"2019","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1159\/000536060","article-title":"The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma","volume":"102","author":"Iwai","year":"2024","journal-title":"Oncology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.21037\/jgo-22-900","article-title":"SGLT-2 as a potential target in pancreatic cancer: The preliminary clue from The Cancer Genome Atlas data","volume":"13","author":"Qiang","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.canlet.2021.07.035","article-title":"SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis","volume":"519","author":"Ren","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhou, J., Zhu, J., Yu, S.J., Ma, H.L., Chen, J., Ding, X.F., Chen, G., Liang, Y., and Zhang, Q. (2020). Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed. Pharmacother., 132.","DOI":"10.1016\/j.biopha.2020.110821"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1590\/s1677-5538.ibju.2018.0271","article-title":"Immunohistochemical expressionof sodium-dependent glucose transporter-2 (SGLT-2) in clear cell renal carcinoma: Possible prognostic implications","volume":"45","author":"Kobayashi","year":"2019","journal-title":"Int. Braz. J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-022-02496-z","article-title":"SGLT2 inhibition restrains thyroid cancer growth via G1\/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways","volume":"22","author":"Wang","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11060-018-2823-7","article-title":"Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas","volume":"138","author":"Kepe","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11060-024-04746-8","article-title":"Effect of Jardiance on glucose uptake into astrocytomas","volume":"169","author":"Ghezzi","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","article-title":"Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences","volume":"302","author":"Sabolic","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E867","DOI":"10.1210\/jc.2012-4205","article-title":"Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus","volume":"98","author":"Polidori","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients with Type 2 Diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_41","unstructured":"Food and Drug Administration (2025, January 07). Inpefa (Sotagliflozin), Lexicon Pharmaceuticals, Drug Trials Snapshots, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-inpefa."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/cpdd.162","article-title":"Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants","volume":"4","author":"Devineni","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","article-title":"Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects","volume":"2","author":"Seman","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2125.2012.04391.x","article-title":"Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin","volume":"75","author":"Boulton","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cts.12549","article-title":"Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin","volume":"11","author":"Raje","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects","volume":"130","author":"Tahara","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2147\/DDDT.S372575","article-title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects","volume":"16","author":"He","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor","volume":"54","author":"Devineni","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpdd.908","article-title":"Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects","volume":"10","author":"Li","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.clinthera.2018.06.015","article-title":"Pharmacokinetics of Single-dose Ertugliflozin in Patients with Hepatic Impairment","volume":"40","author":"Sahasrabudhe","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/10600280231190443","article-title":"A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes","volume":"58","author":"Cowart","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clinthera.2014.12.013","article-title":"Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"37","author":"Devineni","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1124\/dmd.111.040675","article-title":"Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus","volume":"39","author":"Kalgutkar","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.clinthera.2011.09.011","article-title":"Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: An open-label, parallel-group, single-dose study","volume":"33","author":"Kasichayanula","year":"2011","journal-title":"Clin. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.dsx.2019.04.035","article-title":"A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus","volume":"13","author":"Chawla","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40262-020-00875-1","article-title":"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor","volume":"59","author":"Fediuk","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1681\/ASN.2016050510","article-title":"Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule","volume":"28","author":"Ghezzi","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_59","first-page":"364","article-title":"Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes","volume":"40","author":"Ndefo","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(12)60216-5","article-title":"FDA rejects novel diabetes drug over safety fears","volume":"379","author":"Burki","year":"2012","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40264-023-01373-6","article-title":"SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes","volume":"47","author":"Wang","year":"2024","journal-title":"Drug Saf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Shi, N., Shi, Y., Xu, J., Si, Y., Yang, T., Zhang, M., Ng, D.M., Li, X., and Xie, F. (2021). SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front. Public. Health, 9.","DOI":"10.3389\/fpubh.2021.668368"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12299","DOI":"10.1002\/cam4.5927","article-title":"Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study","volume":"12","author":"Chung","year":"2023","journal-title":"Cancer Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"108468","DOI":"10.1016\/j.jdiacomp.2023.108468","article-title":"Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk","volume":"37","author":"Hu","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101500","DOI":"10.1016\/j.diabet.2023.101500","article-title":"Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes","volume":"50","author":"Huang","year":"2024","journal-title":"Diabetes Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13300-015-0128-9","article-title":"Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: The Dapagliflozin Drug Development Program as a \u2019Case Study\u2019","volume":"6","author":"Ptaszynska","year":"2015","journal-title":"Diabetes Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"110621","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.2337\/dc22-1174","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study","volume":"45","author":"Abrahami","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e00145","DOI":"10.1002\/edm2.145","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews","volume":"3","author":"Pelletier","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Rokszin, G., Kiss, Z., Suto, G., Kempler, P., Jermendy, G., Fabian, I., Szekanecz, Z., Poor, G., Wittmann, I., and Molnar, G.A. (2021). Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.725465"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e3784","DOI":"10.1002\/dmrr.3784","article-title":"Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study","volume":"40","author":"Sung","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Chung, M.C., Hsu, H.T., Chang, C.H., Hung, P.H., Hsiao, P.J., Wu, L.Y., Wu, M.J., Shieh, J.J., and Chung, C.J. (2022). Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-13760-7"},{"key":"ref_76","first-page":"2","article-title":"Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors","volume":"10","author":"Perelman","year":"2024","journal-title":"Cardiooncology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"106039","DOI":"10.1016\/j.phrs.2021.106039","article-title":"Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: A meta-analysis of randomized clinical trials","volume":"175","author":"Benedetti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","author":"Luo","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejim.2023.01.021","article-title":"Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis","volume":"110","author":"Chan","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/jgh.16498","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer","volume":"39","author":"Chiang","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Hendryx, M., Dong, Y., Ndeke, J.M., and Luo, J. (2022). Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0274519"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5414\/CP204465","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and pancreatic cancer in the Japanese working-age population","volume":"61","author":"Tanaka","year":"2023","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"106094","DOI":"10.1016\/j.phrs.2022.106094","article-title":"Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis","volume":"177","author":"Cui","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40170-023-00306-2","article-title":"Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: A phase 1b observational study","volume":"11","author":"Park","year":"2023","journal-title":"Cancer Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/0008-5472.CAN-23-1148","article-title":"Glucose deprivation promotes pseudo-hypoxia and de-differentiation in lung adenocarcinoma","volume":"84","author":"Saggese","year":"2023","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Saggese, P., Sellitto, A., Martinez, C.A., Giurato, G., Nassa, G., Rizzo, F., Tarallo, R., and Scafoglio, C. (2020). Metabolic Regulation of Epigenetic Modifications and Cell Differentiation in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12123788"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1878-0261.13508","article-title":"Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1alpha","volume":"17","author":"Biziotis","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"175565","DOI":"10.1016\/j.ejphar.2023.175565","article-title":"Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer","volume":"943","author":"Nalla","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Akingbesote, N.D., Norman, A., Zhu, W., Halberstam, A.A., Zhang, X., Foldi, J., Lustberg, M.B., and Perry, R.J. (2022). A precision medicine approach to metabolic therapy for breast cancer in mice. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03422-9"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced beta-catenin activation","volume":"10","author":"Hung","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhong, J., Sun, P., Xu, N., Liao, M., Xu, C., Ding, Y., Cai, J., Zhang, Y., and Xie, W. (2020). Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin. Biochem. Pharmacol., 175.","DOI":"10.1016\/j.bcp.2020.113856"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Shiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., Yamaguchi, S., Ogasawara, N., Katoh, M., and Itoh, M. (2018). Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-19658-7"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Jojima, T., Wakamatsu, S., Kase, M., Iijima, T., Maejima, Y., Shimomura, K., Kogai, T., Tomaru, T., Usui, I., and Aso, Y. (2019). The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205237"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Abdelhamid, A.M., Saber, S., Youssef, M.E., Gaafar, A.G.A., Eissa, H., Abd-Eldayem, M.A., Alqarni, M., Batiha, G.E., Obaidullah, A.J., and Shahien, M.A. (2022). Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomed. Pharmacother., 145.","DOI":"10.1016\/j.biopha.2021.112455"},{"key":"ref_98","first-page":"1223","article-title":"Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter-1 and lactate dehydrogenase A","volume":"57","author":"Xu","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Ali, A., Mekhaeil, B., Biziotis, O.D., Tsakiridis, E.E., Ahmadi, E., Wu, J., Wang, S., Singh, K., Menjolian, G., and Farrell, T. (2023). The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-05289-w"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/gerona\/glab254","article-title":"Canagliflozin Increases Intestinal Adenoma Burden in Female ApcMin\/+ Mice","volume":"77","author":"Korfhage","year":"2022","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: A master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10571-022-01221-8","article-title":"Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK","volume":"43","author":"Shoda","year":"2023","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.12659\/MSM.902530","article-title":"Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma","volume":"23","author":"Kuang","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2020.09.005","article-title":"An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells","volume":"495","author":"Xie","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metab."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"253","DOI":"10.18433\/jpps32879","article-title":"Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy","volume":"25","author":"Bardaweel","year":"2022","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13340-021-00494-6","article-title":"Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro","volume":"12","author":"Yamamoto","year":"2021","journal-title":"Diabetol. Int."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Li, H., Tong, C.W., Leung, Y., Wong, M.H., To, K.K., and Leung, K.S. (2017). Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00288"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.neo.2021.02.003","article-title":"Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin","volume":"23","author":"Papadopoli","year":"2021","journal-title":"Neoplasia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","article-title":"Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: In Vitro and Molecular Docking Studies","volume":"3","author":"Eliaa","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Nakano, D., Kawaguchi, T., Iwamoto, H., Hayakawa, M., Koga, H., and Torimura, T. (2020). Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232283"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Luo, J., Sun, P., Zhang, X., Lin, G., Xin, Q., Niu, Y., Chen, Y., Xu, N., Zhang, Y., and Xie, W. (2021). Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1alpha Protein Synthesis via AKT\/mTOR Pathway. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413336"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1113\/JP271904","article-title":"Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice","volume":"594","author":"Hirayama","year":"2016","journal-title":"J. Physiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jhbp.1391","article-title":"SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma","volume":"31","author":"Fujiyoshi","year":"2024","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4103\/jcrt.JCRT_963_19","article-title":"Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K\/AKT\/GSK-3beta\/mTOR and Wnt\/beta-catenin pathways; in vitro","volume":"17","author":"Thabet","year":"2021","journal-title":"J. Cancer Res. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Okada, J., Yamada, E., Saito, T., Yokoo, H., Osaki, A., Shimoda, Y., Ozawa, A., Nakajima, Y., Pessin, J.E., and Okada, S. (2020). Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. Molecules, 25.","DOI":"10.3390\/molecules25030495"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1507\/endocrj.EJ15-0396","article-title":"Effect of dapagliflozin on colon cancer cell [Rapid Communication]","volume":"62","author":"Saito","year":"2015","journal-title":"Endocr. J."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Dutka, M., Bobinski, R., Francuz, T., Garczorz, W., Zimmer, K., Ilczak, T., Cwiertnia, M., and Hajduga, M.B. (2022). SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives. Cancers, 14.","DOI":"10.3390\/cancers14235811"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Basak, D., Gamez, D., and Deb, S. (2023). SGLT2 Inhibitors as Potential Anticancer Agents. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071867"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Sun, M., Sun, J., Sun, W., Li, X., Wang, Z., Sun, L., and Wang, Y. (2024). Unveiling the anticancer effects of SGLT-2i: Mechanisms and therapeutic potential. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1369352"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: Hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tem.2020.05.004","article-title":"Rethinking the Relationship between Insulin and Cancer","volume":"31","author":"Vigneri","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.7150\/ijbs.89942","article-title":"The PI3K\/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer","volume":"20","author":"Fontana","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body Fatness and Cancer--Viewpoint of the IARC Working Group","volume":"375","author":"Scoccianti","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s13300-017-0274-3","article-title":"Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)","volume":"8","author":"Matsumura","year":"2017","journal-title":"Diabetes Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40268-016-0137-9","article-title":"Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients","volume":"16","author":"Okamoto","year":"2016","journal-title":"Drugs R D"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrn.2017.168","article-title":"Leptin and the maintenance of elevated body weight","volume":"19","author":"Pan","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/BJ20051578","article-title":"Intracellular signalling pathways activated by leptin","volume":"393","author":"Fruhbeck","year":"2006","journal-title":"Biochem. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1007\/s11033-023-08525-y","article-title":"Obesity and cancer: Focus on leptin","volume":"50","author":"Ayed","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Parida, S., Siddharth, S., and Sharma, D. (2019). Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102519"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.immuni.2013.12.007","article-title":"Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis","volume":"40","author":"Singh","year":"2014","journal-title":"Immunity"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/iub.573","article-title":"The monocarboxylate transporter family--Structure and functional characterization","volume":"64","author":"Halestrap","year":"2012","journal-title":"IUBMB Life"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","article-title":"Monocarboxylate transporters in cancer","volume":"33","author":"Payen","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Liu, Y., and Zhang, W. (2020). The role of HOPX in normal tissues and tumor progression. Biosci. Rep., 40.","DOI":"10.1042\/BSR20191953"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-022-04649-6","article-title":"beta-Hydroxybutyrate suppresses colorectal cancer","volume":"605","author":"Wong","year":"2022","journal-title":"Nature"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0006-2952(02)01220-0","article-title":"G protein-coupled receptor for nicotinic acid in mouse macrophages","volume":"64","author":"Lorenzen","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbrc.2008.08.041","article-title":"The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist","volume":"375","author":"Tang","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Wanders, D., Graff, E.C., White, B.D., and Judd, R.L. (2013). Niacin increases adiponectin and decreases adipose tissue inflammation in high fat diet-fed mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071285"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molcel.2016.03.036","article-title":"Metabolic Regulation of Gene Expression by Histone Lysine beta-Hydroxybutyrylation","volume":"62","author":"Xie","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"109487","DOI":"10.1016\/j.celrep.2021.109487","article-title":"Ketogenesis impact on liver metabolism revealed by proteomics of lysine beta-hydroxybutyrylation","volume":"36","author":"Koronowski","year":"2021","journal-title":"Cell Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s42255-024-01093-w","article-title":"Ketogenic diet reshapes cancer metabolism through lysine beta-hydroxybutyrylation","volume":"6","author":"Qin","year":"2024","journal-title":"Nat. Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.expneurol.2007.12.029","article-title":"Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions","volume":"211","author":"Haces","year":"2008","journal-title":"Exp. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00018-022-04289-z","article-title":"Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin","volume":"79","author":"Olivieri","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13098-023-01085-y","article-title":"Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Wang","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic Inflammation and Insulin Resistance in Obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circ. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","article-title":"Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus","volume":"142","author":"Kurinami","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","article-title":"Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?","volume":"158","author":"Gehrke","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Li, L., Li, Q., Huang, W., Han, Y., Tan, H., An, M., Xiang, Q., Zhou, R., Yang, L., and Cheng, Y. (2021). Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.589273"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Safaie, N., Masoumi, S., Alizadeh, S., Mirzajanzadeh, P., Nejabati, H.R., Hajiabbasi, M., Alivirdiloo, V., Basmenji, N.C., Derakhshi Radvar, A., and Majidi, Z. (2024). SGLT2 inhibitors and AMPK: The road to cellular housekeeping?. Cell Biochem. Funct., 42.","DOI":"10.1002\/cbf.3922"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1871523018666190830100022","article-title":"Anti-inflammatory Property of AMP-activated Protein Kinase","volume":"19","author":"Noor","year":"2020","journal-title":"Anti-Inflamm. Anti-Allergy Agents Med. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"El-Horany, H.E., Atef, M.M., Abdel Ghafar, M.T., Fouda, M.H., Nasef, N.A., Hegab, I.I., Helal, D.S., Elseady, W., Hafez, Y.M., and Hagag, R.Y. (2023). Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2\/AMPK\/Nrf2 Signaling and Targeting Ferroptosis and Autophagy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119481"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"176166","DOI":"10.1016\/j.ejphar.2023.176166","article-title":"Canagliflozin ameliorates ulcerative colitis via regulation of TLR4\/MAPK\/NF-kappaB and Nrf2\/PPAR-gamma\/SIRT1 signaling pathways","volume":"960","author":"Althagafy","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"Shigiyama","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus","volume":"57","author":"Sugiyama","year":"2018","journal-title":"Intern. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced glycation end products and diabetic complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_168","first-page":"45","article-title":"Type 2 diabetes mellitus, oxidative stress and inflammation: Examining the links","volume":"11","author":"Oguntibeju","year":"2019","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13098-024-01280-5","article-title":"SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway","volume":"16","author":"Zeng","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C.S., Nishii, N., and Yamada, H. (2014). Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100777"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Oelze, M., Kroller-Schon, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinssius, E., and Agdauletova, S. (2014). The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112394"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Cai, C., Guo, Z., Chang, X., Li, Z., Wu, F., He, J., Cao, T., Wang, K., Shi, N., and Zhou, H. (2022). Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPKalpha1\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol., 52.","DOI":"10.1016\/j.redox.2022.102288"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Dia, B., Alkhansa, S., Njeim, R., Al Moussawi, S., Farhat, T., Haddad, A., Riachi, M.E., Nawfal, R., Azar, W.S., and Eid, A.A. (2023). SGLT2 Inhibitor-Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A\/20-HETE Signaling Mechanism. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030965"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"eBioMedicine"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.18293","article-title":"Empagliflozin modulates CD4+ T-cell differentiation via metabolic reprogramming in immune thrombocytopenia","volume":"198","author":"Qin","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"112156","DOI":"10.1016\/j.mce.2024.112156","article-title":"SGLT2 knockdown restores the Th17\/Treg balance and suppresses diabetic nephropathy in db\/db mice by regulating SGK1 via Na(+)","volume":"584","author":"Wang","year":"2024","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s43587-024-00642-y","article-title":"SGLT2 inhibition eliminates senescent cells and alleviates pathological aging","volume":"4","author":"Katsuumi","year":"2024","journal-title":"Nat. Aging"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e13108","DOI":"10.1097\/MD.0000000000013108","article-title":"Relationship between oxidative stress and inflammation in hyperuricemia: Analysis based on asymptomatic young patients with primary hyperuricemia","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Peris-Fernandez, M., Roca-Marugan, M., Amengual, J.L., Balaguer-Timor, A., Viejo-Boyano, I., Soldevila-Orient, A., Devesa-Such, R., Sanchez-Perez, P., and Hernandez-Jaras, J. (2024). Uremic Toxins and Inflammation: Metabolic Pathways Affected in Non-Dialysis-Dependent Stage 5 Chronic Kidney Disease. Biomedicines, 12.","DOI":"10.20944\/preprints202402.0580.v1"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic Communication by SGLT2 Inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:38:44Z","timestamp":1759919924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":184,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030466"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030466","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}